Not all individuals with CLL call for therapy. Irrespective of all the latest improvements, the iwCLL nevertheless recommends watchful observation for people with asymptomatic sickness.86 This suggestion is based on at least two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (